<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809132</url>
  </required_header>
  <id_info>
    <org_study_id>U01-AA021893-01</org_study_id>
    <secondary_id>U01AA021893-01</secondary_id>
    <nct_id>NCT01809132</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis</brief_title>
  <official_title>Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mack Mitchell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two different treatments of acute alcoholic hepatitis. The current
      standard of care is treatment with corticosteroids (methylprednisolone). This will be
      compared to treatment with anakinra, pentoxifylline, plus zinc sulfate. The participants
      will be treated and followed for 6 months and the two treatment groups will be compared for
      differences in death rates and laboratory tests that measure liver and gut function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that the syndrome of acute alcoholic hepatitis results
      from severe inflammation and dysregulated cytokines. Steroid monotherapy is not effective in
      all patients and this study will utilize compounds that have the potential to improve gut
      barrier function, to reduce the associated inflammation, and to prevent the development of
      hepatorenal syndrome and other organ failure.

      Patients will be randomized to receive 28 days of methylprednisolone 32 mg daily OR therapy
      that includes a combination of anakinra (interleukin-1 receptor antagonist) 100mg by
      subcutaneous injection daily for 14 days plus pentoxifylline 400 mg orally three times daily
      for one month plus zinc supplements (220 mg of zinc sulfate) given orally for 6 months. This
      combination strategy will address the acute inflammatory component of the disease (anakinra)
      and protect against development of hepatorenal syndrome (pentoxifylline), one of the most
      frequent causes of death in severe acute alcoholic hepatitis, and improve gut mucosal
      integrity (zinc supplements). The primary outcome will be 6 month mortality rate. Secondary
      outcomes will be measured at 30, 90 and 180 days.

      Individuals who are not participating in the interventional arm of the trial will be receive
      standard care and be observed for 6 months. They will be enrolled to have baseline and
      interval health information and laboratory results collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Time to event up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MELD score</measure>
    <time_frame>30, 90, and 180 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Model of End Stage Liver Disease Score calculated from serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory assay for biomarkers of inflammation</measure>
    <time_frame>2,7, 30, 90, and 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum endotoxin, IL-1, TNF-alpha</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acute Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Anakinra &amp; Pentoxifylline &amp; Zinc Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methylprednisolone 32 mg orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.</description>
    <arm_group_label>Anakinra &amp; Pentoxifylline &amp; Zinc Sulfate</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline, generic</description>
    <arm_group_label>Anakinra &amp; Pentoxifylline &amp; Zinc Sulfate</arm_group_label>
    <other_name>Pentoxifylline, generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc Sulfate</intervention_name>
    <description>Zinc Sulfate, nutritional supplement</description>
    <arm_group_label>Anakinra &amp; Pentoxifylline &amp; Zinc Sulfate</arm_group_label>
    <other_name>Zinc Sulfate, generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone, corticosteroid</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Methylprednisolone, generic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide informed consent by subject or appropriate family member

          2. Age between 21-70 years

          3. Recent alcohol consumption &gt; 50 g/d for &gt; 6 months, continuing within two months
             before enrollment

          4. At least 2 of the following symptoms or signs of acute alcoholic hepatitis: Anorexia,
             nausea, RUQ pain, jaundice, leukocytes, hepatomegaly, AND Elevation of AST &gt; 80 U/L,
             but &lt; 500 U/L; AST &gt; ALT and ALT &lt; 200 U/L; total bilirubin &gt; 3 mg/dL AND

          5. Liver biopsy showing alcoholic hepatitis (steatohepatitis) OR ultrasound of liver
             showing increased echogenicity OR CT scan showing cirrhosis or decreased attenuation
             of liver compared to spleen OR MRI showing fatty liver (decreased signaling intensity
             on T1 weighted images)

          6. Model for End-Stage Liver Disease (MELD) ≥ 20 and Maddrey ≥ 32

          7. Willingness to utilize two reliable forms of contraception (both males and females of
             childbearing potential) from screening through the first six weeks of the study.

        Exclusion Criteria:

          1. Hypotension with BP &lt; 80/50 after volume repletion

          2. Pregnancy; incarceration; inability to provide consent or lack of appropriate family
             member

          3. Signs of uncontrolled systemic infection: Fever &gt; 38°C and positive blood or ascites
             cultures on appropriate antibiotic therapy for &gt; 3 days within 3 days of inclusion

          4. Acute gastrointestinal bleeding requiring &gt; 2 units of blood transfusion within the
             previous 4 days

          5. Undue risk from immunosuppression: Positive HBsAg; a positive skin PPD skin test, a
             positive quantiferon, or history of treatment for tuberculosis; history of any
             malignancy except skin cancer but including hepatocellular carcinoma; known HIV
             infection

          6. Previous treatment with corticosteroids or other immunosuppressive medications
             including specific anti-TNF therapy (not including pentoxifylline), calcineurin
             inhibitors within the previous 3 months

          7. Evidence of acute pancreatitis: CT evidence or amylase or lipase &gt; 4 X ULN

          8. Serious cardiac, respiratory or neurologic disease or evidence of autoimmune
             hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease,
             hemochromatosis, secondary iron overload due to chronic hemolysis,
             alpha-1-antitrypsin deficiency

          9. Acute or chronic kidney injury with serum creatinine &gt; 3.0 mg/dl.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack C Mitchell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur J McCullough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig J McClain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyongi Szabo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig J McClain, MD</last_name>
      <phone>502-852-6991</phone>
    </contact>
    <investigator>
      <last_name>Craig J McClain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyongi Szabo, MD</last_name>
      <phone>508-856-5275</phone>
    </contact>
    <investigator>
      <last_name>Gyongi Szabo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur J McCullough, MD</last_name>
      <phone>216-444-2766</phone>
    </contact>
    <investigator>
      <last_name>Arthur J McCullough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mack C Mitchell, MD</last_name>
      <phone>214-648-5036</phone>
    </contact>
    <investigator>
      <last_name>Mack C Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Mack Mitchell</investigator_full_name>
    <investigator_title>Professor of Medicine, Division of Digestive and Liver Diseases</investigator_title>
  </responsible_party>
  <keyword>Hepatitis, alcoholic</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>zinc</keyword>
  <keyword>anakinra</keyword>
  <keyword>glucocorticoids</keyword>
  <keyword>MELD score</keyword>
  <keyword>Intestinal mucosa</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
